Recent SYRS News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 09:03:51 PM
- Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial • Business Wire • 08/12/2024 08:15:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/02/2024 10:39:25 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/31/2024 11:44:08 AM
- Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update • Business Wire • 07/31/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 10:55:07 AM
- Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 • Business Wire • 07/24/2024 11:00:00 AM
- Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression • Business Wire • 06/13/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:30:54 PM
- Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update • Business Wire • 05/14/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:42:01 AM
- Syros to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 01:00:00 PM
- Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 • Business Wire • 05/07/2024 11:00:00 AM
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression • Business Wire • 04/09/2024 11:00:00 AM
- Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2024 08:30:00 PM
- Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update • Business Wire • 03/27/2024 11:30:00 AM
- U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading • IH Market News • 03/27/2024 10:57:08 AM
- Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial • Business Wire • 03/25/2024 11:00:00 AM
- Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 • Business Wire • 03/20/2024 11:00:00 AM
- Syros to Participate in TD Cowen 44th Annual Health Care Conference • Business Wire • 02/27/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:56:21 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:22:30 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:02:26 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM